Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on Actinium Pharmaceuticals, Inc. (ATNM) and wondering who the major players are behind this biopharmaceutical company? As of April 17, 2025, the share price stands at $1.21, a notable shift from $6.67 on April 18, 2024. Institutional investors hold a significant stake, with 9,955,297 shares controlled by 152 institutions. But who are the top dogs, and what's driving their investment decisions? Let's delve into the details of ATNM's investor profile, exploring who's buying and, more importantly, why they're making those moves, especially after the stock experienced a 59% drop on August 5, 2024, closing at $2.48 following an FDA update.

Actinium Pharmaceuticals, Inc. (ATNM) Who Invests in Actinium Pharmaceuticals, Inc. (ATNM) and Why?

Understanding the investor profile of Actinium Pharmaceuticals, Inc. (ATNM) involves examining the various types of investors, their motivations, and the strategies they employ. This provides a comprehensive view of who is investing in the company and the reasons behind their investment decisions. You can find more information about Actinium Pharmaceuticals, Inc. (ATNM) in this link: Actinium Pharmaceuticals, Inc. (ATNM): History, Ownership, Mission, How It Works & Makes Money.

Actinium Pharmaceuticals, Inc. (ATNM) attracts a mix of investor types, each with their own investment styles and objectives:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Retail investors in Actinium Pharmaceuticals, Inc. (ATNM) may be drawn to the company's potential for growth in the biotechnology sector.
• Institutional Investors: These include entities such as mutual funds, pension funds, and insurance companies. Institutional investors often have a longer-term investment horizon and conduct extensive research before investing.
• Hedge Funds: These are investment partnerships that use pooled funds and may employ more aggressive strategies, such as short-selling or leveraging, to maximize returns.

Several factors might attract investors to Actinium Pharmaceuticals, Inc. (ATNM):

• Growth Prospects: Investors may be attracted to Actinium Pharmaceuticals, Inc. (ATNM) due to its growth potential, particularly if the company is developing innovative treatments or therapies.
• Market Position: The company's position within the biotechnology industry can be a significant draw. A strong market presence or a unique niche may appeal to investors.

Different investors may adopt various strategies when investing in Actinium Pharmaceuticals, Inc. (ATNM):

• Long-Term Holding: Some investors may choose to hold shares for an extended period, banking on the company's long-term growth and success.
• Short-Term Trading: Other investors might engage in short-term trading, aiming to profit from short-term price fluctuations.
• Value Investing: Value investors seek to invest in companies that they believe are undervalued by the market, hoping to realize gains as the market recognizes the company's true worth.

Information on Actinium Pharmaceuticals, Inc. (ATNM)'s investor composition can sometimes be gleaned from regulatory filings and financial news sources. These sources may provide insights into the percentage of shares held by institutional investors versus retail investors, as well as any significant changes in ownership.

For example, data regarding institutional ownership can offer clues about the confidence level of larger, more sophisticated investors in Actinium Pharmaceuticals, Inc. (ATNM)’s prospects. Monitoring these trends can provide valuable context for current and prospective investors.

Actinium Pharmaceuticals, Inc. (ATNM) Institutional Ownership and Major Shareholders of Actinium Pharmaceuticals, Inc. (ATNM)

Institutional ownership in Actinium Pharmaceuticals, Inc. (ATNM) reflects the extent to which large financial organizations like mutual funds, pension funds, and hedge funds hold the company’s stock. Analyzing these ownership patterns can provide insights into market sentiment and potential stock performance.

As of December 31, 2024, Actinium Pharmaceuticals, Inc. (ATNM) had an institutional ownership percentage of approximately 30.26%. This figure indicates the proportion of the company's total outstanding shares held by institutional investors. Recent data shows notable activity among these major players.

Here are some of the top institutional investors in Actinium Pharmaceuticals, Inc. (ATNM) based on recent holdings:

• Vanguard Group Inc.: Holding approximately 2,344,532 shares, representing about 2.7% of the outstanding shares.
• BlackRock Inc.: With around 1,665,737 shares, holding approximately 1.9% of the company.
• State Street Corp: Holding approximately 713,227 shares.

Changes in institutional ownership can be a key indicator of investor confidence. Recent filings reveal some significant adjustments in holdings:

• Vanguard Group Inc.: Increased its holdings by 4.0% in the first quarter of 2024.
• BlackRock Inc.: Increased its holdings by 1.6% in the first quarter of 2024.
• State Street Corp: Increased its holdings by 2.4% in the first quarter of 2024.

These increases suggest a growing confidence among these major institutional investors in Actinium Pharmaceuticals, Inc. (ATNM).

Institutional investors play a crucial role in Actinium Pharmaceuticals, Inc. (ATNM)’s stock performance and strategic direction. Their large trading volumes can influence stock prices, and their investment decisions often reflect in-depth research and analysis of the company’s prospects. Active engagement from institutional shareholders can also drive corporate governance improvements and strategic shifts.

Here is a summary of key institutional ownership data for Actinium Pharmaceuticals, Inc. (ATNM):

For more detailed insights into Actinium Pharmaceuticals, Inc. (ATNM), you might find this resource helpful: Actinium Pharmaceuticals, Inc. (ATNM): History, Ownership, Mission, How It Works & Makes Money.

Actinium Pharmaceuticals, Inc. (ATNM) Key Investors and Their Impact on Actinium Pharmaceuticals, Inc. (ATNM)

Understanding the investor profile of Actinium Pharmaceuticals, Inc. (ATNM) provides crucial insights into the company's stability, growth potential, and market perception. Examining who is investing, their motivations, and their recent activities can significantly inform investment decisions.

While specific, real-time data on all individual investors is typically not public, focusing on institutional ownership and major stakeholders offers a clear picture. These entities often have a substantial impact on stock movements and corporate strategy.

Institutional investors are significant players in Actinium Pharmaceuticals, Inc. (ATNM). These may include:

• Hedge Funds
• Mutual Funds
• Pension Funds
• Endowments

These institutions often conduct in-depth research before investing, and their actions can influence market sentiment. Increases in institutional ownership can be seen as a positive signal, suggesting confidence in the company's future prospects. Conversely, a decrease may indicate concerns about performance or market conditions.

Key investors can exert considerable influence on Actinium Pharmaceuticals, Inc. (ATNM) through:

• Voting Rights: Large shareholders have a greater say in corporate governance, including the election of board members and approval of major decisions.
• Activism: Some investors may take an active role, advocating for changes in company strategy, operations, or management.
• Market Impact: Significant buying or selling activity can drive stock price fluctuations, affecting the company's market capitalization.

Recent moves by major investors, such as acquiring or divesting large stakes, are closely watched by the market. These actions can provide clues about investor sentiment and future expectations for Actinium Pharmaceuticals, Inc. (ATNM).

Keeping an eye on Form 4 filings with the SEC can reveal insider transactions, offering insights into the perspectives of company executives and directors. While not always indicative of future performance, these transactions can reflect management's confidence in the company.

Information on significant shareholders can often be found in Actinium Pharmaceuticals, Inc. (ATNM)'s annual reports (10-K) and quarterly reports (10-Q) filed with the Securities and Exchange Commission (SEC). Monitoring these filings provides updated information on ownership structure and any changes in major holdings.

For further insights into the financial health of Actinium Pharmaceuticals, Inc. (ATNM), consider exploring: Breaking Down Actinium Pharmaceuticals, Inc. (ATNM) Financial Health: Key Insights for Investors

Actinium Pharmaceuticals, Inc. (ATNM) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for gauging the potential trajectory of Actinium Pharmaceuticals, Inc. (ATNM). Recent market behavior and analyst perspectives provide valuable insights into how major shareholders influence the company's stock performance and future prospects.

Actinium Pharmaceuticals Inc. (ATNM) closed its last trading session on April 18, 2024, with an increase of 0.75% from its previous closing price, reaching $1.34. During that session, 309,326 shares were traded, contrasting with its average daily volume of 416,394 shares over the past month. Over the last year, Actinium Pharmaceuticals' stock has fluctuated between $0.79 and $2.18.

Here's a snapshot of key stock performance metrics:

• Last Price: $1.34
• 52-Week High: $2.18
• 52-Week Low: $0.79

Institutional investors play a significant role in Actinium Pharmaceuticals, Inc. (ATNM). Examining their activity can offer clues about the stock's potential direction. As of the latest assessments:

• Institutional Ownership: A substantial percentage of Actinium Pharmaceuticals' shares are held by institutions.
• Recent Transactions: Recent filings detail the buying and selling activities of these institutions, reflecting their evolving strategies and outlook on the company.

Reviewing these transactions provides insight into whether institutional investors are increasing or decreasing their stakes, which can influence market sentiment.

Analyst ratings and price targets offer additional perspectives on Actinium Pharmaceuticals, Inc. (ATNM). These assessments consider various factors, including clinical trial results, regulatory milestones, and financial performance. As of recent reports:

• Rating Trend: The general trend in analyst ratings provides a sense of whether experts are becoming more or less optimistic about the stock.
• Price Targets: Average and individual price targets set by analysts indicate potential future stock values based on their analyses.

These insights, while not guarantees, represent informed opinions that can guide investment decisions.

Keep tabs on Actinium Pharmaceuticals, Inc. (ATNM) developments via Mission Statement, Vision, & Core Values of Actinium Pharmaceuticals, Inc. (ATNM).